Pembrolizumab and nivolumab Special Authority data
22 April 2021
Dear [name and contact details withheld]
REQUEST FOR INFORMATION
Thank you for your request dated 7 April 2021 under the Official Information Act 1982 (OIA) for information relating to pembrolizumab and nivolumab. You requested:
…quarter 1 data by month on Special Authority’s – initial and renewal for the 2 immunotherapies funded for melanoma in New Zealand, pembrolizumab and nivolumab…
Special Authority data for pembrolizumab and nivolumab
Following on from our previous response to you 17 February 2021 regarding your request for information, please refer below for an update of pembrolizumab and nivolumab Special Authority application numbers.
Pembrolizumab - SA1910
|
Month submitted |
Initial Applications |
Approvals - initial |
Renewal Applications |
Approval - Renewal |
Total applications |
Total approvals |
|---|---|---|---|---|---|---|
|
2021-01-01 |
22 |
21 |
64 |
59 |
86 |
80 |
|
2021-02-01 |
16 |
14 |
41 |
38 |
57 |
52 |
|
2021-03-01 |
1 |
1 |
61 |
54 |
62 |
55 |
Nivolumab - SA1911
|
Month submitted |
Initial Applications |
Approvals - initial |
Renewal Applications |
Approval - Renewal |
Total applications |
Total approvals |
|---|---|---|---|---|---|---|
|
2021-01-01 |
0 |
0 |
4 |
3 |
4 |
3 |
|
2021-02-01 |
0 |
0 |
0 |
0 |
0 |
0 |
|
2021-03-01 |
0 |
0 |
0 |
0 |
0 |
0 |
Please note:
- The data provided was correct as of 9 April 2021. It is likely incomplete, due to delays in applications being processed and entered into the system.
- The data provided is a count of Special Authority approvals, not patients. They do not represent the number of patients being dispensed the relevant medicine in a given period.
- If a patient has had more than one relevant Special Authority approval, they will be counted more than once in this data.
We trust that this information answers your queries. We are making our information more freely available, so we will now publish selected OIA responses (excluding personal details) on our website. Please get in touch with us if you have any questions about this.
Yours sincerely
Rachel Read
Manager, Policy and Government Services